Literature DB >> 16378985

Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant.

Xueling Wu1, Adam B Parast, Barbra A Richardson, Ruth Nduati, Grace John-Stewart, Dorothy Mbori-Ngacha, Stephanie M J Rainwater, Julie Overbaugh.   

Abstract

Maternal passive immunity typically plays a critical role in protecting infants from new infections; however, the specific contribution of neutralizing antibodies in limiting mother-to-child transmission of human immunodeficiency virus type 1 is unclear. By examining cloned envelope variants from 12 transmission pairs, we found that vertically transmitted variants were more resistant to neutralization by maternal plasma than were maternal viral variants near the time of transmission. The vertically transmitted envelope variants were poorly neutralized by monoclonal antibodies b12 [corrected] 2G12, 2F5, and 4E10 individually or in combination. Despite the fact that the infant viruses were among the most neutralization resistant in the mother, they had relatively few glycosylation sites. Moreover, the transmitted variants elicited de novo neutralizing antibodies in the infants, indicating that they were not inherently difficult to neutralize. The neutralization resistance of vertically transmitted viruses is in contrast to the relative neutralization sensitivity of viruses sexually transmitted within discordant couples, suggesting that the antigenic properties of viruses that are favored for transmission may differ depending upon mode of transmission.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16378985      PMCID: PMC1346878          DOI: 10.1128/JVI.80.2.835-844.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

3.  Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial.

Authors:  R Nduati; G John; D Mbori-Ngacha; B Richardson; J Overbaugh; A Mwatha; J Ndinya-Achola; J Bwayo; F E Onyango; J Hughes; J Kreiss
Journal:  JAMA       Date:  2000-03-01       Impact factor: 56.272

4.  Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.

Authors:  R Hofmann-Lehmann; J Vlasak; R A Rasmussen; B A Smith; T W Baba; V Liska; F Ferrantelli; D C Montefiori; H M McClure; D C Anderson; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; H Katinger; G Stiegler; L A Cavacini; M R Posner; T C Chou; J Andersen; R M Ruprecht
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Maternal HIV-1 antibody and vertical transmission in subtype C virus infection.

Authors:  Hugo Guevara; Jorge Casseb; Lynn S Zijenah; Michael Mbizvo; Leopoldo F Oceguera; Carl V Hanson; David A Katzenstein; R Michael Hendry
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

6.  Characterization of primary isolate-like variants of simian-human immunodeficiency virus.

Authors:  J M Crawford; P L Earl; B Moss; K A Reimann; M S Wyand; K H Manson; M Bilska; J T Zhou; C D Pauza; P W Parren; D R Burton; J G Sodroski; N L Letvin; D C Montefiori
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

Authors:  G Stiegler; R Kunert; M Purtscher; S Wolbank; R Voglauer; F Steindl; H Katinger
Journal:  AIDS Res Hum Retroviruses       Date:  2001-12-10       Impact factor: 2.205

8.  Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections.

Authors:  G C John; R W Nduati; D A Mbori-Ngacha; B A Richardson; D Panteleeff; A Mwatha; J Overbaugh; J Bwayo; J O Ndinya-Achola; J K Kreiss
Journal:  J Infect Dis       Date:  2000-12-15       Impact factor: 5.226

9.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants.

Authors:  S M Wolinsky; C M Wike; B T Korber; C Hutto; W P Parks; L L Rosenblum; K J Kunstman; M R Furtado; J L Muñoz
Journal:  Science       Date:  1992-02-28       Impact factor: 47.728

View more
  172 in total

1.  Viral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission.

Authors:  Philip L Bulterys; Sudeb C Dalai; David A Katzenstein
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

2.  Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.

Authors:  Manish Sagar; Xueling Wu; Sandra Lee; Julie Overbaugh
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 3.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

4.  A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006.

Authors:  Geetha P Bansal
Journal:  Biologicals       Date:  2007-09-21       Impact factor: 1.856

5.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

6.  Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3.

Authors:  Pushpa Jayaraman; Tuofu Zhu; Lynda Misher; Deepika Mohan; LaRene Kuller; Patricia Polacino; Barbra A Richardson; Helle Bielefeldt-Ohmann; David Anderson; Shiu-Lok Hu; Nancy L Haigwood
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Authors:  Rong Rong; Frederic Bibollet-Ruche; Joseph Mulenga; Susan Allen; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Authors:  Catherine A Blish; D Noah Sather; George Sellhorn; Leonidas Stamatatos; Yide Sun; Indresh Srivastava; Susan W Barnett; Brad Cleveland; Julie Overbaugh; Shiu-lok Hu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

9.  An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes.

Authors:  Adam S Dingens; Dana Arenz; Haidyn Weight; Julie Overbaugh; Jesse D Bloom
Journal:  Immunity       Date:  2019-01-29       Impact factor: 31.745

10.  HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response.

Authors:  Anne Piantadosi; Bhavna Chohan; Dana Panteleeff; Jared M Baeten; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh
Journal:  AIDS       Date:  2009-03-13       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.